Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of laboratory and genetic testing (an evidence-based review)

Author:

England J. D.,Gronseth G. S.,Franklin G.,Carter G. T.,Kinsella L. J.,Cohen J. A.,Asbury A. K.,Szigeti K.,Lupski J. R.,Latov N.,Lewis R. A.,Low P. A.,Fisher M. A.,Herrmann D. N.,Howard J. F.,Lauria G.,Miller R. G.,Polydefkis M.,Sumner A. J.

Abstract

Background:Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence-based guidelines regarding the role of laboratory and genetic tests for the assessment of DSP.Methods:A literature review using MEDLINE, EMBASE, and Current Contents was performed to identify the best evidence regarding the evaluation of polyneuropathy published between 1980 and March 2007. Articles were classified according to a four-tiered level of evidence scheme and recommendations were based upon the level of evidence.Results and Recommendations:1) Screening laboratory tests may be considered for all patients with polyneuropathy (Level C). Those tests that provide the highest yield of abnormality are blood glucose, serum B12 with metabolites (methylmalonic acid with or without homocysteine), and serum protein immunofixation electrophoresis (Level C). If there is no definite evidence of diabetes mellitus by routine testing of blood glucose, testing for impaired glucose tolerance may be considered in distal symmetric sensory polyneuropathy (Level C). 2) Genetic testing should be conducted for the accurate diagnosis and classification of hereditary neuropathies (Level A). Genetic testing may be considered in patients with cryptogenic polyneuropathy who exhibit a hereditary neuropathy phenotype (Level C). Initial genetic testing should be guided by the clinical phenotype, inheritance pattern, and electrodiagnostic features and should focus on the most common abnormalities which are CMT1A duplication/HNPP deletion, Cx32 (GJB1), and MFN2 mutation screening. There is insufficient evidence to determine the usefulness of routine genetic testing in patients with cryptogenic polyneuropathy who do not exhibit a hereditary neuropathy phenotype (Level U).AAN= American Academy of Neurology;AANEM= American Academy of Neuromuscular and Electrodiagnostic Medicine;AAPM&R= American Academy of Physical Medicine and Rehabilitation;CMT= Charcot-Marie-Tooth;DSP= distal symmetric polyneuropathy;EDX= electrodiagnostic;GTT= glucose tolerance testing;IFE= immunofixation electrophoresis;QSS= Quality Standards Subcommittee;SPEP= serum protein electrophoresis.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Cited by 204 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Peripheral Neuropathy;Primary Care: Clinics in Office Practice;2024-06

2. Neuropatie nei diabetici;EMC - Neurologia;2024-05

3. A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET;Journal of Pain Research;2024-04

4. CLINICAL PROFILE OF PERIPHERAL NEUROPATHY IN GERIATRIC POPULATION;Asian Journal of Pharmaceutical and Clinical Research;2024-03-07

5. Charcot-Marie-Tooth Disease;Reference Module in Neuroscience and Biobehavioral Psychology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3